Supplies of some once-weekly estradiol patches are due to be discontinued from late 2025, the Department of Health and Social Care (DHSC) has confirmed.
Progynova TS 50micrograms/24hours and 100micrograms/24hours transdermal patches, used for hormone replacement therapy (HRT), will be discontinued from late December 2025 and February 2026 respectively, according to a medicine supply notification.
FemSeven 50micrograms/24hours and 100micrograms/24hours transdermal patches – also once-weekly products – remain available and can support increased demand.
Twice-weekly estradiol patches, including Evorel 50micrograms and 100micrograms and Estraderm MX 50micrograms and 100micrograms, also remain available.
The DHSC said a copy of the supply notification, which includes further information and actions required, has been circulated to all pharmacy NHS email accounts.
Further updates, including any changes to expected discontinuation dates, are available via the online medicines supply tool.
Keep your clinical knowledge up to date with The Pharmacist
Extend your learning and record your learning outcomes
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.